Adaptive Biotechnologies Corporation, a commercial-stage company, advances the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
The company’s immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. The company captures these insights in its dynam...
Adaptive Biotechnologies Corporation, a commercial-stage company, advances the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
The company’s immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. The company captures these insights in its dynamic clinical immunomics database and related antigen annotations, which are underpinned by computational biology and machine learning, and uses them to develop and commercialize clinical products and services that can be tailored to the needs of individual patients.
In 2024, the company reorganized itself around two main businesses: the ‘MRD business,’ consisting of clinical assessment of minimal residual disease (‘MRD’) in lymphoid malignancies, and ‘Immune Medicine’ or the ‘IM business,’ built on drug discovery and development driven by immune medicine.
The MRD business focuses on the use of the company’s highly sensitive, next-generation sequencing (‘NGS’) assay to measure MRD in patients with hematologic malignancies. It consists of its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners to advance drug development efforts (‘MRD Pharma’).
clonoSEQ is the first test authorized by the Food and Drug Administration (‘FDA’) for the detection and monitoring of MRD in patients with multiple myeloma (‘MM’), B cell acute lymphoblastic leukemia (‘ALL’), and chronic lymphocytic leukemia (‘CLL’), and it is also available as a CLIA-validated laboratory developed test (‘LDT’) for patients with other lymphoid cancers, including diffuse large B cell lymphoma (‘DLBCL’) and mantle cell lymphoma (‘MCL’). With its industry-leading sensitivity, clonoSEQ is uniquely situated for MRD testing in lymphoid cancers, both in the clinic and in biopharmaceutical trials. With the use of clonoSEQ, the company is transforming how lymphoid cancers are treated.
The company’s strategic priorities in the IM business include supporting its partner, Genentech, Inc. (‘Genentech’), in its development of TCR-based cell therapies in oncology, and developing targeted therapies using its differentiated precision immunology approach in select autoimmune indications.
The IM business leverages the company’s proprietary ability to sequence, map, pair, and characterize TCRs and B cell receptors (‘BCRs’) at scale. The company has created a powerful data engine to drive the development of novel therapies. These datasets, which it owns, include more than 100,000 signatures of cancer and autoimmune disease, and more than 2,000,000 matches of TCRs to disease-related antigens.
In cancer, the company is working with Genentech under its worldwide collaboration and license agreement (the ‘Genentech Agreement’) to develop TCR-based cell therapies to treat patients with solid tumors. The company’s role is to discover and characterize TCRs against cancer antigens. In 2023, Genentech secured the first FDA-cleared investigational new drug (‘IND’) for a cell therapy product candidate under the Genentech Agreement. This milestone established an important TCR-based cell therapy product candidate proof of concept that supports its antigen-specific TCR discovery approach. In autoimmunity, the company applies its immune medicine platform to discover the specific T cells that are attacking ‘self’ or healthy tissue. It focuses on select autoimmune indications, such as multiple sclerosis (‘MS’) and type 1 diabetes (‘T1D’), among others, where there is still a high unmet need to develop better, more targeted therapies with a better side effect profile. In MS and T1D, for example, the company has successfully identified the subset of autoreactive TCRs that are likely causing these devastating diseases.
Immunosequencing Platform
The company’s immunosequencing platform combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It extracts and interprets insights from the adaptive immune system with the scale, precision, and speed required to enable the design of clinical products tailored to the specific genetics of each patient’s immune system.
The company has developed a combination of technologies to perform the following key functions that broaden its understanding of immune-mediated biology:
Sequencing: The company’s proprietary NGS-based immunosequencing methods provide sequences for single chains of ‘Y-shaped’ TCRs or BCRs, which enables understanding of the quantity and diversity of T cells and B cells in a biological sample. In the context of hematologic malignancies, where B cells and T cells are the cancer cells, the company’s platform technology allows it to identify and quantify residual disease burden (MRD) by sequencing BCR and TCR rearrangements within those cells with a high degree of sensitivity and precision. The company’s sequencing capabilities, together with its massive clinical immunomics database of immune receptor sequences, provide deep insights into individual and collective immune responses at a scale that is thousands of times greater than was previously possible.
Antigen Identification: The company has developed powerful approaches to identify disease-related antigens, which trigger a T-cell response, even at levels of one T-cell in a million (as may occur in autoimmune disorders).
Human leukocyte antigen (‘HLA’)-presented disease-specific antigens: By applying proprietary screening methods, the company can identify TCRs that cluster around a presumably identical HLA-presented antigen and identify that antigen by a process it calls ‘de-orphanization.’ The company’s massive database of TCRs and healthy control samples enables it to rapidly confirm whether such antigens are disease-specific, even if the antigen or its relationship to the disease was previously unknown.
Antigen-TCR mapping: MIRA (Multiplexed Identification of TCR Antigen Specificity) maps millions of TCRs to thousands of clinically relevant Class I and Class II antigens. MIRA is another proprietary method that enables the company to elucidate in silico what potential diseases a patient’s immune system has been exposed to or is actively fighting.
Pair: pairSEQ provides a combinatorial strategy to accurately pair both chains of Y-shaped immune cell receptors at high-throughput, which is challenging to do at scale using other methods because the two chains of the Y-shaped receptors are located on different chromosomes. The ability to accurately pair both chains of the receptors in a sample enables the company to reconstruct receptors for therapeutic purposes.
Characterize: The company’s platform characterizes binding, functionality, and safety properties of antigen-specific, paired TCRs or BCRs. The company’s high-throughput sequencing and antibody discovery process allow it to select from a diversity of potent, naturally occurring, full-length human receptors. The company identifies and focuses on a subset of therapeutic-grade candidates to designate and further develop as TCR or antibody-based therapeutic products.
MRD Business
The MRD business focuses on the use of the company’s highly sensitive, FDA-authorized NGS assay to measure MRD in patients with hematologic malignancies. It consists of its clonoSEQ clinical diagnostic testing service for clinicians and its MRD Pharma service, which consists of offering its clonoSEQ assay to biopharmaceutical partners to advance drug development efforts.
clonoSEQ is the preeminent MRD testing choice for hematological malignancies, with industry-leading sensitivity of 1 out of 1,000,000 cells, given sufficient sample input. By taking a baseline measurement prior to starting therapy and then tracking the number of cells at several time points following therapy initiation, hematologists can improve their ability to assess treatment response, predict long-term patient outcomes, monitor disease burden over time, and detect potential relapse.
With the use of clonoSEQ, the company is transforming how lymphoid cancers are treated by working with providers, biopharmaceutical partners, and payors.
clonoSEQ Clinical Diagnostic Testing
Commercially Promoted Indications
The company’s clonoSEQ diagnostic test detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as MRD. The company considers clonoSEQ has broad applicability across all lymphoid malignancies, including ALL, CLL, MM, and Non-Hodgkins Lymphoma (‘NHL’) conditions, such as DLBCL, MCL, and cutaneous T cell lymphoma (‘CTCL’).
In September 2018, clonoSEQ was granted marketing authorization from the FDA, under the de novo process, for patients with MM and ALL to monitor their MRD from bone marrow samples. In August 2020, the clonoSEQ label was expanded to include patients with CLL from bone marrow and blood samples.
In December 2022, the company launched the commercial promotion of clonoSEQ as a CLIA-validated LDT to detect MRD in blood for patients with DLBCL by measuring circulating tumor DNA (‘ctDNA’), which provides patients and clinicians with a powerful blood-based prognostic tool. The company is advancing the regulatory strategy for its DLBCL test to support clinical adoption and increase its usage by its biopharmaceutical partners.
In November 2024, the company launched the commercial promotion of clonoSEQ as a CLIA-validated LDT to detect MRD in blood for patients with MCL.
The company has a multi-pronged strategy to deepen penetration of clonoSEQ and improve its commercial and operational infrastructure through efforts to:
Increase clinical testing in blood to facilitate adoption for clinicians in the community setting and increase frequency of testing across treatment settings. Testing with blood is less invasive for patients and less expensive as compared to MRD testing from bone marrow samples. Therefore, blood-based MRD testing may enable more frequent monitoring of patients over longer periods of time.
Expand clonoSEQ in NHL: With the end goal of clonoSEQ becoming a universal MRD test for all lymphoid malignancies, the company has developed a robust lifecycle development plan to generate sufficient clinical evidence to support increased adoption across lymphoid malignancies.
Expand patient use cases by continuing to generate clinical evidence in clonoSEQ utility throughout the patient continuum of care. clonoSEQ MRD testing has the potential to inform patient management and support drug development in a wide range of contexts and at multiple time points, both for newly diagnosed and relapsed/refractory patients, and both during and after treatment. In addition to expanding the indications for which clonoSEQ has shown clinical utility, the company’s evidence generation strategy also addresses the goal of expanding patient use cases within existing promoted indications.
Enhance customer experience with EMR integrations: In October 2022, the company entered into a partnership with Epic to integrate clonoSEQ into Epic’s EMR system, which will enable easier test ordering and results access for the clonoSEQ test. As of December 2024, clonoSEQ is integrated into the Epic instances at 18 customer accounts. In 2024, the company entered into a partnership with Flatiron Health, Inc. (‘Flatiron’), a leading provider of electronic health records (‘EHR’) software and services for community oncology, to integrate clonoSEQ into Flatiron’s OncoEMR system. Through 2025, the company expects to integrate more Epic accounts and launch the integration with Flatiron in the community to drive further clonoSEQ adoption.
In addition to these strategies, in January 2025, the company entered into a multi-year exclusive strategic commercial collaboration with NeoGenomics, Inc. (‘NeoGenomics’) that will integrate clonoSEQ with NeoGenomics’ COMPASS and CHART offerings in complex blood cancers. The company has begun to collaborate with NeoGenomics to implement the commercial and operational infrastructure to support its partnership and expects to launch cross-promotional efforts later in 2025.
The company has secured IVDR certification for the clonoSEQ assay to facilitate use of the assay in Europe, and it has licensed its technology to academic and commercial partner labs in Europe, Australia, and Japan as a means to make clonoSEQ available locally, primarily for research purposes, though some limited clinical testing is available in selected regions. In 2025, the company expects to license its technology to a new site in Israel. As the company’s non-U.S. market access efforts continue to progress, it also anticipates expanding clinical use with its current lab partners in several countries.
In July 2022, coverage expansion continued as the company secured Medicare coverage for DLBCL, the most common form of NHL. The company secured clonoSEQ coverage with Medicare for DLBCL patients regardless of line of therapy, treatment regimen, or testing timepoint. clonoSEQ is the first and only MRD test to receive Medicare coverage in DLBCL. The company received Medicare coverage for another NHL condition, MCL, effective July 2024.
The company continues to enhance its average selling price (‘ASP’) for clonoSEQ as it is increasing its investments in revenue cycle management to improve claims collection, such as prior authorizations and the appeals process. Further, the company will continue to sign new contracts with private payors who are not currently contracted with it and improve contracted rates for existing contracted private payors over time.
The company also maintains a patient support program, Adaptive Assist, to facilitate access to clonoSEQ testing services for patients who could benefit from the clinical insights provided by clonoSEQ Clinical Testing. Patients can call to discuss their individual circumstances with one of the company’s dedicated patient support representatives in order to better understand their coverage prior to clonoSEQ testing and to navigate the insurance process, including appeals for denied claims. The company also offers financial assistance for qualified uninsured and under-insured patients who cannot afford their patient financial responsibility for clonoSEQ.
Immune Medicine Business
The company’s immunosequencing approach utilizes multiplex, bias-controlled PCR to accurately and quantitatively sequence, map, pair, and characterize millions of TCRs and BCRs at scale. The proprietary datasets the company has generated to date include more than 100,000 signatures of disease (such as cancer and autoimmune conditions), and over 2,000,000 matches of paired TCRs to disease-related antigens.
The company is developing a comprehensive map of the interaction between the immune system and disease (the ‘TCR-Antigen Map’) for use in identifying and validating disease signatures to improve the treatment of various immune-mediated diseases. Supported in part by a collaboration agreement with Microsoft Corporation (‘Microsoft’) that it entered into in December 2017 (the ‘Microsoft Agreement’), the company worked with Microsoft through 2024 to enable access to the necessary machine learning and computational infrastructure to build its TCR-Antigen Map, initially for diagnostic purposes.
Drug Discovery
The company is focusing its drug discovery programs to develop therapies on its own or in partnership.
Strategic Collaborations and Other Agreements
Genentech Agreement
In December 2018, the company entered into the Genentech Agreement to develop, manufacture, and commercialize novel neoantigen-directed T cell therapies for the treatment of a broad range of cancers. Pursuant to the Genentech Agreement, the company is responsible for the screening and identification of TCRs that can most effectively recognize and directly target specific neoantigens, while Genentech is responsible for clinical, regulatory, and commercialization efforts.
Revenue Interest Purchase Agreement
In September 2022, the company entered into a Revenue Interest Purchase Agreement (the ‘Purchase Agreement’) with OrbiMed Royalty & Credit Opportunities IV, LP (‘OrbiMed’), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the ‘Purchasers’).
Intellectual Property
As of December 31, 2024, the company owned or controlled 416 active issued patents and 70 patent applications whose claims are intended to cover what it does, what it plans to do, and what others might do to compete with it. From the company’s earliest patent filings in 2009, its portfolio has been tailored to reflect its efforts to harness the adaptive immune system for research, diagnostic, and therapeutic applications. The company’s patent claims extend to not only adaptive immune receptor molecules, but also to uniquely powerful techniques for sequencing immune cell receptors, determining clonality and immune competency, diagnosing disease, predicting responses to immunotherapy, and identifying new drug candidates. The company’s granted patent protection generally expires in years ranging from 2029 to 2040.
Intellectual Property Portfolio by the Numbers
As of December 31, 2024, the company’s intellectual property portfolio consisted of the following: 847 patent applications filed worldwide directly or in conjunction with a co-owner or licensor since 2009; 70 pending patent applications; 416 issued and allowed patents across the company’s immune medicine platform, including more than 151 patents related to diagnostic approaches in lymphoid malignancies; 24 patent families directed to methods and tools useful in the company’s immune medicine platform for non-target specific immunosequencing and research; 17 patent families directed to methods and tools useful in diagnosis, prognosis, and disease monitoring, including clonoSEQ, certain diagnostic methods, and TCR-antigen binding; 12 patent families directed to methods and tools useful in drug discovery, including the company’s drug discovery screening processes, MIRA, and pairSEQ; 1 patent family directed to SARS-CoV-2 vaccines; 11 patent families directed to novel antigen targets and immune medicine-based therapeutic modalities; 4 patent families directed to gene sequencing technology; and 28 trademarks registered and pending registration worldwide.
Patent Portfolio
The company has developed an expansive patent portfolio in commercially important markets with claims to critical aspects of its technology, beginning with its first patent applications exclusively licensed from Fred Hutchinson Cancer Research Center (‘Fred Hutch’) in 2009. The company’s ongoing patent strategy is to generate a return on its patenting investments, which values substantive quality over volume to build a defensible moat around the technology it uses, as well as what others might develop to design around its position.
Methods of Measuring Adaptive Immunity
In 2009, a U.S. provisional patent application was filed to pursue protection for immunosequencing by the company’s co-founder, Dr. Harlan Robins. The invention broadly relates to methods for assessing the adaptive immune system status of individuals. Rearranged V and J segment genes of TCRs or BCRs are targeted as biomarkers for assessing the status of the immune system at one or more points in time. Granted claims extend to the use of particular sets of amplification primers, while pending claims are being pursued to capture additional assessment techniques. Licensed exclusively to the company by Fred Hutch, the application has since spawned 28 additional patent applications, many of which had been granted as of December 31, 2024, including U.S. Patent No. 9,809,813.
Optimizing Nucleic Acid Amplification Reactions
Amplification of nucleic acids can result in over- or under-representation of the amplified molecules, misrepresenting the number present in the source material, such as a blood sample. Dr. Robins invented a method to correct for such bias, thereby improving the precision of PCR-based quantification of TCR and BCR coding sequences in a sample. The claimed approach utilizes synthetic templates, reflecting nucleic acid sequences for rearranged V and J receptor segments in the sampled cells. Twenty-three related patent applications have since been filed, many of which had been granted as of December 31, 2024, including U.S. Patent Nos. 9,371,558 and 10,214,770.
Diagnosing and Monitoring Disease
In connection with the company’s acquisition (‘Sequenta Acquisition’) of Sequenta, Inc. (‘Sequenta’) in 2015, the company purchased Sequenta’s extensive patent portfolio. The portfolio includes 124 patent applications, which disclose and claim methods to identify and quantify T cell-based immune responses to antigen exposure using NGS. TCR and BCR DNA, ribonucleic acid, or cell-free DNA from samples, including blood and bone marrow, are used to detect, prognose, and monitor disease, including autoimmune disease, infection, and cancer. Sixty-two patents had been granted in the portfolio as of December 31, 2024, including U.S. Patent Nos. 8,628,927 and 8,236,503.
The company’s diagnostic methods also apply to the detection of MRD (the target of the company’s B cell-based clonoSEQ diagnostic test for assessing how disease burden changes in response to treatment or during remission) and T-Detect (the company’s T cell-based diagnostic tests). Multiple patents have been granted from additional applications relating to MRD assessment, diagnostic methods, and diagnostically significant TCRs filed by the company, including U.S. Patent Nos. 9,824,179 and 11,047,008. Additional patent applications are pending for TCR-based diagnostic signals in specific indications, including COVID-19.
TCR-Antigen Binding
The company continues to make significant progress in its understanding of the T-cell mediated response across different indications. The company filed 10 related patent applications for methods to produce antigen-exposed enriched T cell populations and identify their antigen specificities by comparison to a pre-exposure population of cells or by use of an algorithm. The company has filed additional patent applications relating to algorithmic-based methods to characterize antigen specificities.
MIRA
The company developed and is pursuing patent protection for bioinformatic-based methods to determine the antigen specificity of TCRs by exposing T cells to a panel of multiple antigens. Antigen exposure can be performed by incubation or presentation; for example, it can be performed via recombinant expression in another cell. These methods may also be used to pair the two TCR chains, as well as to identify high avidity TCRs. Several patents had been granted as of December 31, 2024, including U.S. Patent No. 10,066,265.
pairSEQ
In nature, TCRs and BCRs exist as a heterodimer of paired chains, each of which is encoded on a different chromosome. Immunosequencing reveals the nucleotide structure of each individual chain, but not which chains match as cognate pairs. The company developed and is pursuing patent protection for multiple bioinformatic-based approaches to pairing the two chains of TCRs and BCRs, including one deployed in the company’s pairSEQ technique. The company’s methods also allow for the identification of receptor chain pairs, which are specific to particular antigen targets. Thirty-one related patent applications have been filed, 12 of which had matured into granted patents as of December 31, 2024, including U.S. Patent No. 10,077,478.
Assessing Responsiveness to Immunotherapy
Leveraging the company’s immunosequencing technologies, the company developed methods for predicting responses to immunotherapy, vaccines, and infection. To those ends, rearranged TCR or BCR sequences are quantified and their levels or frequencies compared at different points in time. Twenty-one related patent applications have been filed, 8 of which had been granted as of December 31, 2024, including U.S. Patent No. 10,221,461.
Therapeutic Antibodies
The company developed a therapeutic antibody discovery process called TruAB, from which neutralizing antibodies have been and are being produced against target antigens in conditions, such as SARS-CoV-2, Type 1 diabetes, influenza, Respiratory Syncytial Virus, inflammatory bowel disease, and MS. Patent applications across 11 patent families for a number of these antibodies have been filed and are pending.
Vaccines
Together with the company’s partner Nykode Therapeutics, the company filed a patent application, which is pending and directed to COVID-19 vaccines, the development of which was informed by its immunosequencing-based drug discovery efforts.
Therapeutic TCRs
The company has a granted patent application for TCRs responsive to WT-1 antigens with potential utility in cell therapy against WT-1 related cancers. The company has pursued a patent application for TCRs responsive to other cancer antigens, which are of interest in its collaboration with Genentech.
In-Licensed and Acquired Intellectual Property Rights
While the company has developed the majority of its immune medicine platform, products, and services, it occasionally licenses or acquires third-party owned inventions to bolster the strength of its patent estate and ensure freedom to operate.
Early work by Dr. Robins with Fred Hutch led to discoveries around immunosequencing methods and tools covered by 128 patents and patent applications in the U.S. and abroad, which the company exclusively licensed. The company’s rights are for all fields of use worldwide and are sublicensable. To the extent any licensed granted patent rights extend to products or services sold by the company, it pays Fred Hutch a royalty rate of 0.75% of net sales on licensed products.
Through the company’s Sequenta Acquisition, the company also obtained an exclusive paid-up license, with rights to sublicense, to patents filed in the U.S., Europe, Australia, and China owned by iRepertoire, Inc. The license is for worldwide use in diagnosis, prognosis, treatment, and monitoring of any proliferative disorder for which rearranged nucleic acids capable of encoding an immune receptor, whether productive or unproductive, or functional or nonfunctional, of a cell, excluding tumor infiltrating lymphocytes, of the proliferative disorder can be used as markers for the disorder, including, but not limited to, lymphoid and myeloid proliferative disorders, such as ALL, CLL, acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin’s and NHL, plasma cell neoplasms, such as MM, monoclonal gammopathy of undetermined significance, monoclonal B cell lymphocytosis, and myelodysplastic syndromes.
In addition to the patent estate acquired from Sequenta, the company also acquired ownership of immunosequencing-related patent portfolios from Imdaptive, Inc. and ImmunID S.A.S.
Government Regulation
The company’s core research product in IM, Adaptive Immunosequencing, is a research use only (‘RUO’) tool in the U.S. that provides data to third parties, such as biopharmaceutical companies that are themselves engaged in the research and development of potential diagnostic and therapeutic products and services for which they may later pursue investigation and clearance, authorization, or approval from regulatory authorities, such as the FDA.
In August 2020, the company received FDA clearance for clonoSEQ, following a 510(k) submission, for CLL in bone marrow, as well as blood samples. The company also received FDA clearance in 2021 for ALL from blood samples, launched in DLBCL and MCL, subtypes of NHL, under CLIA as a LDT, and is actively advancing validation studies in certain other NHL sub-types, such as CTCL.
clonoSEQ obtained a CE mark in May 2019 for all B-cell malignancies with blood and bone marrow, and in August 2024, the company announced that clonoSEQ received IVDR 2017/746 Class C risk certification issued by the Notified Body (BSI), which will be a requirement as of May 2026. The IVDR requires, among other things, that clonoSEQ meet conformity assessments, performance evaluations, and performance studies to improve health and safety and adopt a systematic post-market surveillance plan and report that includes the manufacturer’s trend reporting.
As a clinical laboratory, the company must obtain a CLIA certificate based on the complexity of testing performed at the laboratory, such as a Certificate of Compliance for high-complexity testing. In addition to CLIA requirements, the company elects to participate in the accreditation program of the CAP. The U.S. Centers for Medicare & Medicaid Services (‘CMS’), the agency that oversees CLIA, has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of CMS inspections for accredited laboratories. Therefore, because the company is accredited by the CAP Laboratory Accreditation Program, it is deemed to also comply with CLIA. The company’s laboratory holds the required licenses for Maryland, Rhode Island, Pennsylvania, New York, and California.
Three principal data protection-related regulations with which the company is required to comply have been issued in final form under HIPAA and HITECH: privacy regulations, security regulations, and security breach notification regulations.
In the U.S., there are various fraud and abuse laws with which the company must comply, and it is subject to regulation by various federal, state, and local authorities, including CMS, other divisions of HHS, such as the Office of Inspector General (‘OIG’), the U.S. Department of Justice (‘DOJ’), and individual U.S. Attorney offices within the DOJ, and state and local governments. The company also may be subject to foreign fraud and abuse laws.
The company’s laboratories are subject to extensive requirements related to workplace safety established by the U.S. Occupational Safety and Health Administration. These include requirements to develop and implement programs to protect workers from exposure to blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.
History
The company was founded in 2009. It was incorporated in the state of Washington in 2009. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in 2011.
